INTRODUCTION
============

At the time of diagnosis, approximately 20%--25% of colorectal cancer patients already have metastasis. In these individuals, the treatment strategy will be palliative or curative according to disease status \[[@b1-ac-2019-03-04-1]\]. In recent years, even unresectable metastatic lesions can be resected if the tumor response is favorable to previous systemic chemotherapy. Adam et al. \[[@b2-ac-2019-03-04-1]\] found that, among 1,104 initially unresectable colorectal liver metastases patients, 138 with good response (12.5%) underwent hepatic resection after an average of 10 sessions of chemotherapy, and a 5-year survival rate of 33% was achieved versus a rate of 5% in patients who did not undergo resection. In some cases of resectable metastasis, upfront systemic chemotherapy is recommended for various reasons. First, upfront chemotherapy can play a role as an in vivo chemosensitivity assay and can be used in conjunction with metabolic imaging (e.g., fluorodeoxyglucose - positron emission tomography) to reflect differences in the biologic tumor associated with various responses. Further, chemically reducing the tumor prior to surgery can lessen the frequency of tumor cell shedding during surgery and improve the rate of R0 resection \[[@b3-ac-2019-03-04-1]\]. The goal of systemic chemotherapy for these patients is to cure the disease or prolong survival and maintain quality of life as long as possible \[[@b1-ac-2019-03-04-1]\].

Several developments have improved systemic chemotherapy in patients with metastatic colorectal cancer. Introduction of combination chemotherapy protocols and addition of new biological target agents such as bevacizumab and cetuximab have led to significant advances in tumor response after chemotherapy for metastatic colorectal cancer patients \[[@b4-ac-2019-03-04-1]\]. In particular, the target agent acts on a specific molecule of cancer cells to exert its anticancer effect, which is less harmful to normal cells than other types of chemotherapy and has the potential to cause fewer side effects. In a recent review, addition of a biologic agent to conventional chemotherapy increased the rate of conversion to a resectable state in patients with unresectable metastatic colorectal cancer \[[@b5-ac-2019-03-04-1]\].

However, systemic chemotherapy alone rarely cures metastatic colorectal cancer. In patients with metastatic colorectal cancer, curative resection (R0) is the only therapeutic option for longterm survival \[[@b6-ac-2019-03-04-1]\]. In addition, in potentially resectable stage IV colon cancer patients with good tumor response after upfront chemotherapy, R0 resection can be achieved \[[@b7-ac-2019-03-04-1]\].

However, administration of chemotherapy may lead to higher perioperative morbidity. Oxaliplatin is related to sinusoidal liver lesions, and irinotecan is related to steatohepatitis. We also do not yet fully understand the potential toxicity of antiangiogenesis agents like bevacizumab \[[@b8-ac-2019-03-04-1]\]. In addition, combined resection for primary tumor and metastasis usually requires many surgical procedures and long operation times. Furthermore, patients may receive a long duration of upfront chemotherapy or chemoradiation therapy. These concerns may place a burden on the surgeon in making decisions about the operation regarding timing of surgery after upfront chemotherapy. Additionally, the optimal timing of surgery and cessation of systemic chemotherapy prior to surgery are not well-established.

The aim of our study was to evaluate perioperative clinical short-term outcomes of curative surgery after upfront chemotherapy for patients with metastatic colon cancer.

METHODS
=======

Patients
--------

We retrospectively analyzed 146 patients diagnosed with metastatic colon cancer who underwent surgical resection before or after systemic chemotherapy at Yonsei University Severance Hospital, South Korea, between January 2010 and October 2015. Patients with peritoneal metastasis were excluded from the present study. We collected information on all study participants from their medical records and divided them into the 2 groups: the surgery first group of 80 initially 'resectable' patients who underwent surgical resection followed by adjuvant chemotherapy, and the upfront chemotherapy group of 66 initially 'potentially resectable' or 'unresectable' patients who underwent upfront chemotherapy followed by surgical resection. We retrospectively compared these 2 groups. To evaluate the distribution, number, and size of the lesions before initiation of treatment, image examinations of the thoracic, abdominal, and pelvic areas were performed. All decisions for treatment were made by a multidisciplinary team composed of surgeons, medical oncologists, radiation oncologists, and radiologists. To achieve improved accuracy in decision-making and in treatment plans as well as better surgical and oncologic outcomes and increased patient satisfaction, all patients were evaluated with consideration of the various aspects during a multidisciplinary team conference. Resectability of the primary tumor and metastatic lesions was mainly assessed via reinterpretation by and discussion of the imaging results by radiologists and surgeons. We initially identified the primary tumor as 'unresectable' when it showed extensive involvement of a major structure like the vena cava, superior mesenteric vessel, pancreas, or duodenum. For hepatic metastatic lesions, when the remnant parenchyma of the liver was expected to be less than 30% of the total volume after resection, we defined this as 'unresectable.' When resection was needed rather than lobectomy, or if a patient had insufficient respiratory function, we categorized the cancer as 'unresectable' lung metastasis \[[@b9-ac-2019-03-04-1]\]. For patients with 'unresectable' or 'potentially resectable' tumors, a chemotherapeutic agent was administered according to the guidelines of National Health Insurance of Korea. The physician chose the target agent in consultation with the patient according to the results of a K-ras mutation test. Cetuximab or bevacizumab was used for patients without the K-ras mutation, and bevacizumab was chosen for patients with the Kras mutation. During patient follow-up, imaging studies were repeated to investigate treatment response and resectability. According to the RECIST (response evaluation criteria in solid tumor) \[[@b10-ac-2019-03-04-1]\], we defined a 'partial response' as a ≥50% decrease in tumor size on imaging studies. 'Progressive disease' was defined as a \>25% increase in tumor size or detection of newly developed lesions. Otherwise, cases were defined as 'stable disease.' In this study, 33 patients (50%) showed 'partial response,' 32 patients (48.5%) had 'stable disease,' and only 1 patient (1.5%) showed 'progressive disease' based on one newly developed liver metastasis on imaging during follow-up. When a tumor converted to resectable during follow-up, we considered surgery with a curative intent. This study was approved by the Institutional Review Board (IRB) of Severance Hospital Yonsei University Health System (IRB No. 2018-0566-001). The need for informed consent was waived by the IRB.

Clinical variables
------------------

Data on patient and tumor characteristics, upfront chemotherapy regimens, operative factors, and clinical factors related to postoperative outcome were collected from medical records. Patient and tumor characteristics comprised age; sex; weight; height; body mass index (BMI); American Society of Anesthesiologists (ASA) physical status classification; primary colon cancer location; organ with metastasis; tumor, lymph node (N), and metastasis (M) stages in accordance with the American Joint Committee on Cancer staging \[[@b11-ac-2019-03-04-1]\]; and histology of the tumor. Upfront chemotherapy regimens were evaluated for agents used, duration and cycles of therapy, and time from completion of chemotherapy to surgery. Operative variables were surgical approach method, surgical procedures for primary colon cancer, surgical procedures for metastatic lesions, and open conversion.

Operative management
--------------------

All patients underwent primary resection of colon cancer according to location, and resection of metastatic lesions was performed. Some patients underwent a staged operation following consideration of the location and size of the metastatic lesions and the comorbidity and condition of the patient. In patients with more than 2 organ metastases, simultaneous resection was performed when possible. However, in most cases, a staged operation was performed considering the width of resection. Meanwhile, if it was impossible to perform resection or if the risk was greater than the anticipated benefit, a second operation was not performed.

Postoperative outcomes
----------------------

Postoperative short-term clinical outcomes of time to first fluid intake, time to first flatus, and length of hospital stay were evaluated. Postoperative complications were evaluated and graded using the Clavien-Dindo classification system \[[@b12-ac-2019-03-04-1]\], a previously defined grading system for surgical complications.

Statistical analysis
--------------------

We performed all statistical analyses using IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, USA). Categorical variables were analyzed using the chi-square or Fisher exact test, while continuous variables were analyzed using Student t-test or MannWhitney U-test. A significance level (P-value) less than 0.05 was considered statistically significant.

RESULTS
=======

Patient and tumor characteristics
---------------------------------

Patient and tumor characteristics are listed in [Table 1](#t1-ac-2019-03-04-1){ref-type="table"}. There were more T4 patients in the Surgery first group (surgery first group: 33.8% vs. upfront chemotherapy group: 6.1%) and more T3 patients in the upfront chemotherapy group (surgery first group: 61.3% vs. upfront chemotherapy group: 83.3%), possibly due to tumor shrinkage caused by upfront chemotherapy. In comparison, age, sex, weight, height, BMI, ASA physical status classification, primary tumor site, metastasis site, N stage, M stage, and histology did not differ significantly between the 2 groups. In both groups, the most frequent primary colon cancer site was the sigmoid colon (surgery first group: 50.0% vs. upfront chemotherapy group: 56.1%), and the most frequent metastatic organs were the liver and lungs (surgery first group: 92.5% and 12.5%, respectively, vs. upfront chemotherapy group: 98.5% and 16.7%).

Upfront chemotherapy was administered to all upfront chemotherapy group patients ([Tables 2](#t2-ac-2019-03-04-1){ref-type="table"}, 3). Combination therapies containing oxaliplatin or irinotecan (folinic acid + 5-fluorouracil + oxaliplatin \[FOLFOX\]; capecitabine + oxaliplatin \[XELOX\]; or folinic acid + 5-fluorouracil + irinotecan \[FOLFIRI\]) were adapted. Forty-four patients received the following target agents: bevacizumab (n = 23; 52.3%), cetuximab (n = 20; 45.5%), and aflibercept (n = 1; 2.3%). The median duration of upfront chemotherapy was 3 months (range, 0--32 months), and the median cycle number for chemotherapy was 6 (range, 2--46 cycles). Additionally, the median time interval from completion of upfront chemotherapy and combined surgery was 6.4 weeks (range, 3.7--57 weeks). In patients who received bevacizumab, the median chemotherapy duration was 2 months (range, 1--32 months), the median number of chemotherapy cycles was 6 (range, 4--46 cycles), and the median time interval for completion of chemotherapy and surgery was 6.8 weeks (range, 4--35 weeks). Because of the high risk of recurrence, systemic chemotherapy was performed in both groups after surgery.

Operative management
--------------------

All patients underwent combined surgery for primary tumor and metastatic lesions ([Table 4](#t4-ac-2019-03-04-1){ref-type="table"}). Open surgery was most common in both groups (surgery first group: 60% vs. upfront chemotherapy group: 87.9%). In the surgery first group, more laparoscopic surgery was performed (surgery first group: 40% vs. upfront chemotherapy group: 9.1%). Conversion rates between the 2 groups were not significantly different (surgery first group: 0% vs. upfront chemotherapy group: 3%). Hepatic resections were classified according to the segmental anatomy of the liver as defined by Couinaud \[[@b13-ac-2019-03-04-1]\]. We defined major liver resection as removal of 4 or more liver segments, and this type was performed more often in the upfront chemotherapy group (surgery first group: 8.1% vs. upfront chemotherapy group: 21.5%). In surgery for lung metastasis, an initial combined operation was more common in the surgery first group (surgery first group: 70% vs. upfront chemotherapy group: 9.1%). Meanwhile, a staged operation or no resection was performed in some cases based on the distribution of lesions or comorbidity of the patient. For liver metastasis, 5 staged liver resections were performed (surgery first group: 1.4% vs. upfront chemotherapy group: 6.2%). For lung metastasis, 7 staged resections were conducted only in the upfront chemotherapy group (surgery first group: 0% vs. upfront chemotherapy group: 63.6%). However, in 6 additional cases, planned staged resection for lung metastasis could not be performed due to poor patient condition and progression of metastasis (surgery first group: 30% vs. upfront chemotherapy group: 27.2%). All patients who experienced metastasis to para-aortic lymph nodes underwent curative para-aortic lymph node dissection.

Postoperative outcomes
----------------------

There was no difference between the 2 groups in postoperative clinical course ([Table 5](#t5-ac-2019-03-04-1){ref-type="table"}). The median length of postoperative care was 10 days (range, 5--77 days) in the surgery first group and 12 days (range, 4--47 days) in the upfront chemotherapy group. A total of 58 postoperative complications developed in 37 patients (46.3%) in the surgery first group versus 82 postoperative complications in 40 patients (60.6%) in the upfront chemotherapy group ([Table 5](#t5-ac-2019-03-04-1){ref-type="table"}). However, there was no significant difference in overall complication rate between the 2 groups (surgery first group: 46.3% vs. upfront chemotherapy group: 60.6%; P = 0.084). There was a notable difference in incidence of postoperative ascites (surgery first group: 2.5% vs. upfront chemotherapy group: 15.2%; P = 0.006) and pulmonary complications (surgery first group: 10% vs. upfront chemotherapy group: 24.2%; P = 0.021), as both occurred more often in the upfront chemotherapy group. Conversely, however, there was no difference between the 2 groups in terms of surgical site infection, bowel anastomotic leakage or bile leakage, or postoperative bleeding after surgery. In the upfront chemotherapy group, there was no bleeding or anastomotic leakage in any patient who received bevacizumab. There was no difference between the 2 groups when classified according to the Clavien-Dindo method (P = 0.263). There was no difference between the 2 groups in terms of major complications of grade III or higher (surgery first group: 18.9% vs. upfront chemotherapy group: 27.5%; P = 0.374). There was one case that needed intensive care unit (ICU) admission following reoperation in both groups (surgery first group: 1.3% vs. upfront chemotherapy group: 1.5%). Reoperation was performed due to bowel anastomotic leakage in the surgery first group and due to bile leakage in the upfront chemotherapy group. One patient in the surgery first group died within 30 days of surgery after ICU care due to postoperative renal failure and pulmonary sepsis.

DISCUSSION
==========

Although metastatic colorectal cancer is generally incurable, resection of oligometastatic disease has curative potential \[[@b14-ac-2019-03-04-1]\]. Furthermore, with the development of systemic chemotherapy, patients with 'unresectable' or 'potentially resectable' metastatic colorectal cancer are more likely to undergo surgical resection following upfront chemotherapy. This conversion therapy has been the subject of recent attention.

It may be natural for surgical oncologists to actively consider surgical resection for patients with 'unresectable' or 'potentially resectable' metastatic colorectal cancer. However, with extensive surgical resection and toxicity of systemic chemotherapy, it may be difficult to make aggressive decisions due to concerns about patient recovery after surgery. In addition, the optimal timing of appropriate surgery and of preoperative chemotherapy discontinuation have not yet been established.

To alleviate these concerns, it is necessary to determine whether preoperative chemotherapy leads to substantially increased postoperative complications in patients who receive upfront chemotherapy followed by surgical resection. Several studies have recently reported on the practicality of upfront chemotherapy in unresectable metastatic colorectal cancer patients \[[@b2-ac-2019-03-04-1], [@b5-ac-2019-03-04-1], [@b15-ac-2019-03-04-1]-[@b17-ac-2019-03-04-1]\], finding an improvement of resectability after upfront chemotherapy in patients with metastatic colorectal cancer, with most procedures performed in patients with liver metastasis. None of the studies focused on short-term outcomes in patients with metastatic colorectal cancer who underwent surgery after upfront chemotherapy. Thus, the present study has several strengths. This study was performed only in patients with solid organ metastatic colorectal cancer and those with peritoneal metastasis. Chemotherapeutic agents used in treatment were modern protocols, reflecting the use of current standards of practice. Furthermore, this study specifically investigated complications known to be associated with chemotherapeutic agents.

In this investigation, we reviewed postoperative clinical course and complications in patients who underwent surgical resection after upfront chemotherapy. We compared the results obtained with those of patients who underwent surgical resection first and investigated whether there were any substantive differences between the 2 groups. In terms of postoperative short-term clinical outcomes, there was no difference between the 2 groups. Postoperative complications developed in 46.3% patients in the surgery first group and 60.6% patients in the upfront chemotherapy group. Most of the complications were minor, and there was no difference between the 2 groups in grade III or more major complications (surgery first group: 18.9% vs. upfront chemotherapy group: 27.5%; P = 0.374).

It is well-known that oxaliplatin increases the risk of sinusoidal obstruction syndrome \[[@b18-ac-2019-03-04-1]\]. A recent publication from Volk et al. \[[@b19-ac-2019-03-04-1]\] demonstrated that preoperative administration of bevacizumab is associated with a strong reduction of total sinusoidal obstruction syndrome incidence. In that report, they also found that, while there was no difference in perioperative morbidity and mortality, there was a significant increase in wound complications in patients who received bevacizumab. In addition, a study by Vauthey et al. \[[@b20-ac-2019-03-04-1]\] revealed an increase in postoperative morbidity rates in patients who developed steatohepatitis. In their study, although there was no association between type of chemotherapy and postoperative complications, there was a trend toward increased postoperative morbidity in patients who underwent a longer duration of chemotherapy. Importantly, in this study, there was no significant increase in hepatobiliary or wound complications, bowel anastomotic leakage, or postoperative bleeding in patients in the upfront chemotherapy group. Although the upfront chemotherapy group had a higher incidence of postoperative ascites, these patients were more unresectable than those in the surgery first group due to the presence of more advanced liver metastatic lesions at the time of diagnosis. This led to more major liver resection after chemotherapy compared to patients in the surgery first group. Furthermore, in all cases, ascites was well-controlled with diuretic use alone. In our study, there was no increase in liver-related complications, especially in the upfront chemotherapy group. This occurrence may be due to the beneficial effects of preoperative bevacizumab administration mentioned by Volk et al. \[[@b19-ac-2019-03-04-1]\] or to development and implementation of postoperative care and surgical techniques. In this regard, further investigations will be needed. In our study, major liver resection (i.e., involving more than 4 segments) was performed in 21.5% of the upfront chemotherapy group. In 4 patients, the associating liver partition and portal vein ligation in staged hepatectomy approach were performed in relation to the extent of hepatic metastasis. There were no liver-related complications noted in our study.

There was no bleeding or anastomotic leakage in patients who received bevacizumab. This finding may support the idea that there is no need to delay surgery due to concern for toxicity caused by chemotherapy or the postoperative bleeding or anastomotic leakage known to be increased by bevacizumab.

In our study, upfront chemotherapy did not significantly increase postoperative complications. In particular, the incidence of specific complications known to be increased by chemotherapy was not substantially greater. These results were possible because of careful patient selection and appropriate treatment planning through a multidisciplinary team approach.

Our study has several limitations to consider. Since this study is a retrospective analysis of a single institution's experience with a small number of patients, we cannot make definitive conclusions about the safety and feasibility of upfront chemotherapy. In addition, it is difficult to assess the number and severity of complications correctly in a retrospective study. Furthermore, there is controversy regarding the definition of resectability. Although the treatment plan was chosen by a multidisciplinary team approach, without clear criteria, we determined resectability based on extent of metastatic disease and functional reserve of the remnant organ region. However, this study addresses the simple but important topic of evaluation of the association between upfront chemotherapy and postoperative morbidity in patients with metastatic colon cancer and may be helpful in decision-making for patients who require surgery after upfront chemotherapy.

In this study, we demonstrated that postoperative complications were not particularly increased in metastatic colon cancer patients who received upfront chemotherapy followed by curative surgery. There was no significant increase in hepatotoxicity, anastomotic leakage, or postoperative bleeding complications known to be associated with systemic chemotherapy. In these patients, focusing on the toxicity of chemotherapy should not interfere with the surgical decision in cases where surgery is necessary. Upfront chemotherapy followed by curative surgery in well-selected metastatic colon cancer patients is a possible treatment option in terms of safety and feasibility. Careful patient selection and treatment planning are important, including consideration of patient comorbidities and extent of surgery, through the multidisciplinary team approach.

No potential conflict of interest relevant to this article was reported.

###### 

Baseline demographic and clinicopathological characteristics

  Characteristic                     Surgery first (n = 80)   Upfront chemotherapy (n = 66)   P-value
  ---------------------------------- ------------------------ ------------------------------- ---------
  Age (yr)                           61.31 ± 11.91            59.00 ± 9.20                    0.199
  Sex                                                                                         0.937
   Male                              49 (61.3)                40 (60.6)                       
   Female                            31 (38.8)                26 (39.4)                       
  Weight (kg)                        62.37 ± 9.88             61.56 ± 11.26                   0.647
  Height (cm)                        162.87 ± 8.08            161.95 ± 7.09                   0.471
  Body mass index (kg/m^2^)          23.41 ± 2.66             23.34 ± 3.17                    0.879
  ASA PS classification ≥ III        14 (17.5)                16 (24.2)                       0.316
  K-ras status                                                                                0.031
   Wild type                         22 (27.5)                32 (48.5)                       
   Mutant                            28 (35.0)                15 (22.7)                       
   Unknown                           30 (37.5)                19 (28.8)                       
  Primary tumor site                                                                          0.605
   Cecum                             3 (3.8)                  2 (3.0)                         
   Ascending colon                   19 (23.8)                12 (18.2)                       
   Hepatic flexure                   5 (6.3)                  1 (1.5)                         
   Transverse colon                  4 (5.0)                  4 (6.1)                         
   Splenic flexure                   1 (1.3)                  0 (0)                           
   Descending colon                  7 (8.8)                  10 (15.2)                       
   Sigmoid colon                     40 (50.0)                37 (56.1)                       
   Ascending colon + sigmoid colon   1 (1.3)                  0 (0)                           
  Metastatic site                                                                             
   Liver                             74 (92.5)                65 (98.5)                       0.128
   Lung                              10 (12.5)                11 (16.7)                       0.475
   Para-aortic lymph node            5 (6.3)                  8 (12.1)                        0.215
   Adrenal gland                     0 (0)                    1 (1.5)                         1
   Diaphragm                         1 (1.3)                  0 (0)                           1
  T stage                                                                                     \<0.001
   T0, no residual cancer            1 (1.3)                  4 (6.1)                         
   T1                                0 (0)                    0 (0)                           
   T2                                3 (3.8)                  3 (4.5)                         
   T3                                49 (61.3)                55 (83.3)                       
   T4a                               21 (26.3)                4 (6.1)                         
   T4b                               6 (7.5)                  0 (0)                           
  N stage                                                                                     0.43
   N0                                19 (23.8)                16 (24.2)                       
   N1a                               15 (18.8)                10 (15.2)                       
   N1b                               20 (25.0)                20 (30.3)                       
   N1c                               3 (2.2)                  1 (1.5)                         
   N2a                               9 (11.3)                 13 (19.7)                       
   N2b                               14 (17.5)                6 (9.1)                         
  M stage                                                                                     0.105
   M1a                               66 (82.5)                47 (71.2)                       
   M1b                               14 (17.5)                19 (28.8)                       
  Histology                                                                                   0.372
   Well-differentiated               3 (3.8)                  4 (6.1)                         
   Moderately differentiated         74 (92.5)                59 (89.4)                       
   Poorly differentiated             1 (1.3)                  3 (4.5)                         
   Mucinous                          2 (2.5)                  0 (0)                           

Values are presented as mean ± standard deviation or number (%).

ASA PS, American Society of Anesthesiologists physical status.

###### 

Details of chemotherapy (n = 66)

  Variable                                                    Value
  ----------------------------------------------------------- ---------------
  Regimen of upfront chemotherapy                             
   FOLFOX^[a](#tfn1-ac-2019-03-04-1){ref-type="table-fn"}^    38 (57.6)
   FOLFIRI^[b](#tfn2-ac-2019-03-04-1){ref-type="table-fn"}^   27 (40.9)
   XELOX^[c](#tfn3-ac-2019-03-04-1){ref-type="table-fn"}^     1 (1.5)
  Use of molecular target agent                               44 (66.7)
   Bevacizumab                                                23 (52.3)
   Cetuximab                                                  20 (45.5)
   Aflibercept                                                1 (2.3)
  Duration of chemotherapy (mo)                               3 (0--32)
  Time interval between chemotherapy and surgery (wk)         6.4 (3.7--57)
  Cycles of chemotherapy                                      6 (2--46)

Values are presented as number (%) or median (range).

FOLFOX = folinic acid + 5-fluorouracil + oxaliplatin.

FOLFIRI = folinic acid + 5-fluorouracil + irinotecan.

XELOX = capecitabine + oxaliplatin.

###### 

Details of adjuvant chemotherapy

  Variable                                                    Surgery first (n = 80)   Upfront chemotherapy (n = 66)   P-value
  ----------------------------------------------------------- ------------------------ ------------------------------- ---------
  Regimen of adjuvant chemotherapy                                                                                     \<0.001
   FOLFOX^[a](#tfn4-ac-2019-03-04-1){ref-type="table-fn"}^    65 (81.3)                32 (48.5)                       
   FOLFIRI^[b](#tfn5-ac-2019-03-04-1){ref-type="table-fn"}^   3 (3.8)                  29 (43.9)                       
   XELOX^[c](#tfn6-ac-2019-03-04-1){ref-type="table-fn"}^     3 (3.8)                  1 (1.5)                         
   FL^[d](#tfn7-ac-2019-03-04-1){ref-type="table-fn"}^        1 (1.3)                  0 (0)                           
   No adjuvant chemotherapy                                   8 (10.0)                 4 (6.1)                         
  Use of molecular target agent                                                                                        \<0.001
   Cetuximab                                                  1 (1.3)                  15 (23.1)                       
   Bevacizumab                                                9 (11.4)                 17 (26.2)                       
   No target agent                                            70 (87.5)                34 (51.5)                       
  Cycles of chemotherapy                                      12 (0--12)               6 (0--16)                       \<0.001

Values are presented as number (%) or median (range).

FOLFOX = folinic acid + 5-fluorouracil + oxaliplatin.

FOLFIRI = folinic acid + 5-fluorouracil + irinotecan.

XELOX = capecitabine + oxaliplatin.

FL = 5-fluorouracil + leucovorin.

###### 

Operative management

  Variable                                    Surgery first (n = 80)   Upfront chemotherapy (n = 66)   P-value
  ------------------------------------------- ------------------------ ------------------------------- ---------
  Open conversion                             0 (0)                    2 (3.0)                         0.203
  Surgical approach                                                                                    \<0.001
   Open                                       48 (60.0)                58 (87.9)                       
   Laparoscopic                               32 (40.0)                6 (9.1)                         
   Robotic                                    0 (0)                    2 (3.0)                         
  Simultaneous resection                      76 (95.0)                52 (78.8)                       0.003
  Staged resection for metastasis             1 (1.3)                  11 (16.7)                       0.001
  Failed staged resection for metastasis      3 (3.8)                  3 (4.5)                         1.000
  Surgery for primary tumor                                                                            0.218
   Anterior resection                         40 (50.0)                37 (56.1)                       
   Right hemicolectomy                        29 (36.3)                16 (24.2)                       
   Left hemicolectomy                         8 (10.0)                 12 (18.2)                       
   Segmental resection of transverse colon    1 (1.3)                  1 (1.5)                         
   Right hemicolectomy + anterior resection   2 (2.5)                  0 (0)                           
  Surgery for liver metastasis                                                                         \<0.001
   Major liver resection (≥4 segments)        6 (8.1)                  14 (21.5)                       
   Minor liver resection (\<4 segments)       25 (33.7)                31 (47.7)                       
   Wedge resection or RFA only                42 (56.7)                16 (24.6)                       
   Staged resection                           1 (1.4)                  4 (6.2)                         
  Surgery for lung metastasis                                                                          0.008
   Wedge resection under VATS                 7/10 (70.0)              1/11 (9.1)                      
   No resection                               3/10 (30.0)              3/11 (27.2)                     
   Staged resection                           0/10 (0)                 7/11 (63.6)                     

Values are presented as number (%).

RFA, radiofrequency ablation; VATS, video-assisted thoracic surgery.

###### 

Postoperative outcomes

  Variable                                                        Surgery first (n = 80)   Upfront chemotherapy (n = 66)   P-value
  --------------------------------------------------------------- ------------------------ ------------------------------- ---------
  Time to first fluid intake (day)                                2 (1--25)                2 (1--6)                        0.570
  Time to first flatus (day)                                      4 (1--9)                 4 (1--7)                        0.770
  Length of hospital stay (day)                                   10 (5--77)               12 (4--47)                      0.470
  Reoperation                                                     1 (1.3)                  1 (1.5)                         1.000
  Complications                                                   37 (46.3)                40 (60.6)                       0.084
  Fever                                                           15 (18.8)                20 (30.3)                       0.104
  Ascites                                                         2 (2.5)                  10 (15.2)                       0.006
  Chyle leakage                                                   3 (3.8)                  4 (6.1)                         0.701
  Ileus                                                           14 (17.5)                8 (12.1)                        0.366
  Cardiac                                                         0 (0)                    2 (3)                           0.203
  Pulmonary                                                       8 (10.0)                 16 (24.2)                       0.021
  Urinary tract infection                                         0 (0)                    1 (1.5)                         0.452
  Voiding difficulty                                              3 (3.8)                  2 (3.0)                         1.000
  Renal                                                           1 (1.3)                  1 (1.5)                         1.000
  Delirium                                                        1 (1.3)                  1 (1.5)                         1.000
  Bleeding                                                        0 (0)                    1 (1.5)                         0.452
  Anastomotic leakage                                             1 (1.3)                  2 (3.0)                         0.590
  Bile leakage                                                    0 (0)                    2 (3.0)                         0.203
  Superficial SSI                                                 6 (7.5)                  7 (10.6)                        0.512
  Organ/space SSI                                                 2 (2.5)                  4 (6.1)                         0.410
  Life-threatening complication requiring ICU management (G≥IV)   2 (2.5)                  1 (1.5)                         1.000
  Reoperation due to anastomotic leakage                          1 (1.3)                  0 (0)                           
  Reoperation due to bile leakage                                 0 (0)                    1 (1.5)                         
  Septic pneumonia                                                1 (1.3)                  0 (0)                           
  Clavien-Dindo classification                                                                                             0.263
   I                                                              3 (8.1)                  6 (15.0)                        
   II                                                             27 (72.9)                23 (57.5)                       
   IIIA                                                           5 (13.5)                 10 (25.0)                       
   IIIB                                                           0 (0)                    0 (0)                           
   IVA                                                            1 (2.7)                  1 (2.5)                         
   IVB                                                            0 (0)                    0 (0)                           
   V                                                              1 (2.7)                  0 (0)                           
  Total                                                           37                       40                              
  Major complication (G≥IIIA)                                     7 (18.9)                 11 (27.5)                       0.374

Values are presented as median (range) or number (%).

SSI, Surgical site infection; ICU, intensive care unit.
